Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes2006 · 102 citations
2. 2Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study2017 · 12 citations
3. 3Effects of sitagliptin beyond glycemic control: focus on quality of life2013 · 43 citations
4. 4Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus2021 · 7 citations
5. 5Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin2007 · 526 citations